95 results about "Coronary heart disease" patented technology

The invention discloses a cardiac function rehabilitation state monitoring method for coronary heart disease postoperative population. The method comprises the following steps: constructing a third-order dynamic baseline adaptive to postoperative pathological evolution; carrying out stress-physiological coupling modeling on the basis of a double-AI (Artificial Intelligence) collaborative architecture; and carrying out trend early warning of equal-condition longitudinal pairing. The heart function rehabilitation state monitoring system comprises an electrocardiosignal preprocessing unit, the electrocardiosignal preprocessing unit is connected with a multi-dimensional electrocardiosignal feature extraction unit, and the multi-dimensional electrocardiosignal feature extraction unit is connected with a third-order individualized baseline management unit and a front stress recognition AI unit. And the third-order individualized baseline management unit and the front stress identification AI unit are respectively connected with the core correlation deduction AI unit. According to the method and system for monitoring the cardiac function rehabilitation state of the crowd after the coronary heart disease operation, dynamic baseline construction and the pathological evolution rule after the coronary heart disease operation are deeply bound, and the problem of high false alarm of a traditional fixed baseline in the early stage of the operation is thoroughly solved through triple-stage design and a dual calibration mechanism.

An apparatus for identifying the progression of coronary heart disease has been disclosed. The apparatus includes at least processor and a memory communicatively connected to the processor. The memory instructs the processor to receive a subject profile associated with a subject, wherein the subject profile comprises a plurality of electrocardiogram (ECG) data. The memory instructs the processor to identify contextual data as a function of the subject profile. The memory instructs the processor to generate a set of cardiac scores as function of the contextual data and the plurality of ECG data using a set of cardiac machine learning models. The memory instructs the processor to select at least one stage of coronary heart disease from a plurality of stages of coronary heart disease of the subject as a function of the set of cardiac scores.

The invention provides a coronary heart disease recurrence risk assessment method and device, equipment and a storage medium, and relates to the technical field of medical data processing. The method comprises the following steps: acquiring dynamic behavior data, physiological data and static risk indexes of a target patient; calculating a treatment compliance index and a rehabilitation health index of the target patient based on the dynamic behavior data and the physiological data of the target patient; and inputting the treatment compliance index, the rehabilitation health index and the static risk index into a trained coronary heart disease recurrence risk scoring model to obtain a coronary heart disease recurrence risk score of the target patient. According to the method, objective and quantitative recurrence risk scores can be obtained, more accurate decision support is provided for clinicians, and early warning and personalized intervention can be realized, so that the prognosis of patients is improved, and the medical cost is reduced.

The invention belongs to the field of biological medicine industry, and discloses a peripheral blood marker and system for identifying the severity of viral myocarditis or coronary artery stenosis. The inventor finds for the first time that the average value of LRG1 in blood is not obviously changed compared with that of a normal person when mild and moderate myocarditis and microcirculation angina pectoris with normal coronary artery or coronary artery stenosis smaller than 10% exist, and the blood LRG1 is obviously increased when the coronary artery stenosis of the coronary heart disease exceeds 70%; when severe myocarditis occurs, the blood LRG1 is also obviously increased, so that the increase of the blood LRG1 is a blood marker for patients with severe myocarditis or severe coronary artery lesion, and the blank that blood indexes are lacked in the prior art to prompt the patients to have severe coronary artery stenosis is filled. By detecting the LRG1 content of the peripheral blood and combining with other conventional examinations, the severity of myocarditis or coronary stenosis can be simply, accurately and quickly distinguished, and a corresponding basis is provided for subsequent accurate treatment.

The invention provides an application of a super enhancer inhibitor JQ-1 in preparation of peripheral artery disease related drugs, relates to the technical field of biomedicine, and discloses a core effect of the super enhancer inhibitor JQ-1 in peripheral artery disease ischemia repair. The traditional Chinese medicine composition can significantly accelerate blood flow recovery of ischemic limbs, up-regulate mRNA and protein expression of a vascular marker CD31 in gastrocnemius muscle tissues, effectively increase vascular density and promote angiogenesis. Aiming at the defects of the existing treatment means in the aspect of ischemic tissue angiogenesis, the application provides a brand new molecular targeted treatment scheme for high-risk groups such as patients with diabetes-related peripheral artery diseases, and can significantly reduce the risk of lower limb amputation and the incidence rate of related cardiovascular adverse events such as coronary heart disease and stroke; the technical blank of specific targeted therapy of peripheral artery diseases is filled, a solid scientific basis and a key direction are provided for research and development of novel drugs, and the specific targeted therapy method has extremely high clinical application value and wide research and development prospects.

The utility model belongs to the technical field of medical instruments, and particularly relates to a coronary heart disease PCI postoperative patient heart rehabilitation exercise auxiliary tool which comprises a base, an anti-skid rubber mat, a handle and a fixing column are arranged on the base, an electric lifting rod is arranged in the fixing column, and the output end of the electric lifting rod is connected with a mounting seat. A controller, a motor, a worm and a shaft rod are arranged in the mounting base, a worm wheel connected with the worm in a meshed mode is arranged on the shaft rod, a containing cavity is formed in the mounting base, a pull strap is arranged in the containing cavity, the shaft rod penetrates through the two ends of the mounting base to be connected with an external connecting rod, and the connecting rod is composed of a telescopic inner rod and an outer rod. By means of the rehabilitation training device, the movement requirements of the upper limbs and the lower limbs of a patient can be met, the patient can be driven to move passively under driving of the motor, and the rehabilitation training effect is effectively improved.

The invention discloses a multi-omics-based coronary heart disease hierarchical diagnosis system and application thereof, and relates to application of personal information in a system for diagnosing whether a subject has no coronary heart disease (NCA) or suffers from the coronary heart disease, and the coronary heart disease comprises stable coronary heart disease (sCAD) and acute coronary syndrome (ACS). The multi-dimensional feature set is constructed by integrating clinical, microbial and metabolic features, potential information provided by data of different dimensions is fully utilized, and the diagnostic performance of the model is remarkably improved; through a Boruta algorithm and an SHAP framework, a series of new metabolite and microbial biomarker information is found, and the method can be used for accurately distinguishing the coronary heart disease and the stable coronary heart disease acute coronary syndrome.

A traditional Chinese medicine formula for treating blood vessel clogging belongs to the field of traditional Chinese medicine formulas, and comprises the following main raw materials: 29-31 parts of black pearl, 11-13 parts of codonopsis pilosula, 7-9 parts of saffron crocus, 8-10 parts of angelica sinensis, 190-210 parts of leek, 9-11 parts of pseudo-ginseng, 37-43 parts of hawthorn, 95-105 parts of astragalus membranaceus, 18-22 parts of kudzu vine root, 8-10 parts of peach kernel, 8-10 parts of prepared rehmannia root, 9-11 parts of radix rehmanniae, 11-13 parts of white paeony root, 3 parts of red ginseng, 9-11 parts of radix ophiopogonis, 14-16 parts of spina date seed, 11-13 parts of Chinese yam, 14-15 parts of schisandra chinensis, 9-11 parts of polygonum multiflorum, 7-9 parts of cinnamon, 18-21 , 13-15 parts of anise and 12-14 parts of rhizoma polygonati. The traditional Chinese medicine composition has an obvious improvement effect on coronary artery insufficiency, myocardial ischemia, mitral valve, tricuspid valve, aortic valve regurgitation, chronic heart failure, patients needing operation bypass stenting, angina pectoris, myocardial infarction sequelae, cerebral ischemia, cerebrovascular sequelae and other symptoms caused by cardiac insufficiency, the dosage is small, the effect is fast, the cure rate is high, relapse is not prone to occurring, and the traditional Chinese medicine composition is suitable for clinical application. The effects of tonifying qi and activating blood, dredging channels and relieving pain, eliminating phlegm and removing blood stasis, tonifying heart and soothing nerves and the like can be achieved.

The application provides a heart activity monitoring method and a wearable device, and relates to the technical field of terminals. The application monitors heart activity of a user through a wearable device, determines whether the user is in a plurality of preset scenes which are prone to induce coronary heart disease, realizes more timely coronary heart disease warning, and avoids missed diagnosis. The method comprises the following steps: after the wearable device determines that the user is in a preset scene according to at least one of first data monitored by a first sensor, second data monitored by a second sensor and third data monitored by a third sensor, the wearable device reminds the user to perform electrocardiogram measurement. And in response to a user input instruction, the wearable device acquires electrocardiogram data of the user through an electrocardiogram sensor. Then, the wearable device divides the risk of the heart activity in combination with the first data and / or the third data and the electrocardiogram data of the user.

This invention provides a wearable myocardial oxygenation monitoring device based on optical path arrangement, comprising a detection component and a control component integrated into a flexible layer. The detection component includes multi-wavelength light sources arranged at an angle of 5° to 20° to the sagittal plane of the human body, detection components partitioned according to coordinate systems of 180° to 240° and 315° to 45°, and diagonally arranged electrocardiogram electrodes. The light sources correspond to the anatomical structure of the anterior interventricular groove of the heart. The control component achieves synchronous signal acquisition and processing via an FPC circuit board. Through precise anatomical positioning, partitioned detection, and flexible fit design, this invention solves the problem of difficulty in distinguishing the functional differences between the left and right ventricles in existing technologies. An adaptive light intensity modulation mechanism based on BMI ensures the optimal balance between signal quality and energy efficiency for different body types. Multi-data fusion enhances the early warning sensitivity of myocardial ischemia, making it suitable for people of different body types and providing a reliable tool for early screening of coronary heart disease.

The invention provides a coronary heart disease echocardiogram pathological feature extraction method and system. Static structure features and myocardial function features of the heart of a target coronary heart disease patient are determined through an ultrasonic video stream of the heart of the target coronary heart disease patient; determining a region mapping matrix of a relationship between a coronary artery blood supply region of the target coronary heart disease patient and a myocardial injury state according to the static structural characteristics and the myocardial functional characteristics, and determining boundary sharpening development of a pathological region in the heart of the target coronary heart disease patient according to the region mapping matrix; acquiring a myocardial movement track of the target coronary heart disease patient, and determining a longitudinal strain gradient of a basal segment and a cardiac apex segment of the heart of the target coronary heart disease patient according to the myocardial movement track; and based on the boundary sharpening development and the longitudinal strain gradient of the pathological area and in combination with the clinical pathological data of the target coronary heart disease patient, generating the cardiac physical characteristics of the target coronary heart disease patient. According to the scheme, the static structure and the dynamic function of the heart can be effectively associated and fused to extract the coronary heart disease echocardiogram features.

The present invention relates to products and compositions and their uses. In particular, the invention relates to nucleic acid products that interfere with the expression of the LPA gene or inhibit its expression, preferably for use as a treatment / treatment, prevention or reduction of the risk of (an individual) suffering from cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome associated with elevated levels of Lp(a) particles.

A diagnostic tool includes a sensor for capturing at least one biosignal produced by a patient's heart and a computer device that implements a neural network iteratively trained via machine learning to generate a prediction about a heart condition of the patient. After the neural network is trained, the computer device can convert the at least one biosignal to a multi-dimensional input matrix for the deep neural network generated from a number (N) of biosignals captured by the sensor. The computer device then processes the multi-dimensional input matrix through the deep neural network, which subsequently outputs the prediction about the heart condition of the patient.

A B-cell specific octamer-binding protein 1 super-enhancer ribonucleic acid (BOB1-seRNA) and an application thereof are provided. The nucleotide sequence of the BOB1-seRNA is shown in SEQ ID NO: 1. Through experiments, it further confirms that the BOB1-seRNA is downregulated in patients with coronary heart disease and can be used in preparation of a product for diagnosing or predicting the coronary heart disease. The use of this molecular marker can be used for early diagnosis of the coronary heart disease, which is rapid and effective. It is not only of great significance for early treatment of the coronary heart disease and saving medical costs, but also provides therapeutic targets and important basis for clinical applications such as gene therapy and drug therapy.

Disclosed herein is a method for detecting cardiomyopathy and heart failure in a subject, the method involving assaying a sample from the subject for decrease in gene or protein expression of a Obg Like ATPase 1 (OLA1) and / or the presence of a Y254C mutation in OLA1, thereby detecting cardiomyopathy and heart failure in the subject. Also disclosed is a method for treating cardiomyopathy, heart failure, myocardial infarction or heart attack, ischemic heart disease, coronary heart disease and hypertrophic cardiomyopathy in a subject, the method involving administering to the subject an expression vector comprising a nucleic acid sequence encoding wild-type Obg Like ATPase 1 (OLA1) operably linked to an expression control sequence.

The invention relates to a preparation method of sugar-free hawthorn and poria cocos granules. The sugar-free hawthorn and poria cocos granules comprise the following raw materials: poria cocos, scorched hawthorn and coix seeds. The sugar-free auxiliary material is one or two or more of mannitol, erythritol and maltitol. The sugar-free hawthorn and poria cocos granules meet the requirements of patients with diabetes mellitus, obesity, hyperlipidemia, coronary heart disease and the like on forbidding to eat sugar, and the clinical application range is widened.

The invention provides a method for predicting coronary artery stenosis degree based on a tongue picture of a patient with coronary heart disease. The method comprises the steps of obtaining a data set; the data set comprises electronic medical record information, blood examination indexes, cardiac ultrasound indexes, electrocardiograms and tongue pictures of the coronary heart disease patient; dividing the preprocessed data set into a training set and a test set according to a preset proportion; building a deep learning network model; inputting the training set into the deep learning network model for training and optimization, and storing the final optimized deep learning network model; and inputting the test set into the finally optimized deep learning network model to obtain a prediction result of the coronary artery stenosis degree of the coronary heart disease patient. According to the method, the coronary artery stenosis degree is judged according to the tongue picture, the electrocardiogram, the cardiac ultrasound index and the blood examination index of the patient with the coronary heart disease, tongue picture features extracted from the tongue picture are converted into quantifiable coronary artery stenosis noninvasive screening targets, and traditional Chinese and western medicine combined diagnosis and treatment intellectualization is promoted.

This invention relates to the field of biomedical technology, specifically to the use of the N-terminal fragment of insulin-like growth factor binding protein-4 (IGF-4) in the clinical assessment of heart failure and coronary artery disease. The N-terminal fragment of IGF-4 is obtained by catalytic hydrolysis of IGF-4 by pregnancy-associated plasma protein A. Clinical assessment of heart failure includes diagnosing or assisting in the diagnosis of heart failure, or assessing or assisting in the prognostic risk of heart failure. Clinical assessment of coronary artery disease includes assessing or assisting in the prognostic risk of coronary artery disease. By detecting the content of the N-terminal fragment of IGF-4 in a sample, heart failure can be diagnosed or assisted in the diagnosis, and the prognosis of heart failure and coronary artery disease can be assessed or assisted in, demonstrating good clinical assessment efficacy.

A system for early warning of coronary heart disease. A computer device comprises a memory, a processor, and a computer program stored on the memory. The processor executes the computer program to implement the following steps: receiving methylation level data of a DNA methylation marker combination of a potential coronary heart disease patient and a healthy control sample, establishing a mathematical model, and determining a threshold; and inputting methylation level data of the DNA methylation marker combination of a subject to be tested and substituting same into the mathematical model to obtain a detection index, and comparing the detection index with the threshold to obtain a conclusion of whether a sample to be tested belongs to the potential coronary heart disease patient or the healthy control. The present invention has important scientific significance and clinical application value in early warning of coronary heart disease and diagnosis and treatment of coronary heart disease.

The invention discloses a young coronary heart disease marker HTRA1 and application thereof, and belongs to the technical field of biomarkers. The expression level of the HTRA1 in serum of young coronary heart disease patients is obviously increased, the ROC value of the HTRA1 in the young coronary heart disease patients is high, healthy control and young coronary heart disease groups can be effectively distinguished, it is prompted that the HTRA1 has high value for predicting and diagnosing the young coronary heart disease, and the HTRA1 can be used for developing corresponding diagnostic reagents and kits and has good application prospects. The kit is used for detecting the content of HTRA1 in a human body sample, so that auxiliary diagnosis of the young coronary heart disease is realized. The diagnostic reagent and the kit have the advantages of being high in specificity, high in sensitivity, easy and convenient to operate and the like, and important reference bases can be provided for early discovery and treatment of the young coronary heart disease.

The application belongs to the technical field of biological medicine, and discloses a novel polypeptide with lipid-lowering effect. In view of the problem that polypeptides are prone to be enzymolyzed in the gastrointestinal tract and difficult to play obvious effect in the body, a novel polypeptide is designed, and the amino acid sequence of the polypeptide is GQAIWMY. The polypeptide GQAIWMY has lipid-lowering capacity, is not prone to be degraded by gastrointestinal enzymes and is more stable, and can be used for preparing drugs for preventing or treating cardiovascular diseases (such as hyperlipidemia, atherosclerosis, coronary heart disease) and fatty liver diseases.

The application discloses a magnesium complex taking aspirin or an oxygen-deficiency promoting derivative thereof as a ligand, a preparation method and application thereof in preparation of a medicine for treating coronary heart disease. The structural formula of the magnesium complex is shown in the following formula I-IV: the magnesium carbonate is reacted with nitric acid to obtain magnesium nitrate; the aspirin is reacted with sodium bicarbonate to obtain a neutral sodium salt of aspirin; the neutral sodium salt of aspirin is reacted with the magnesium nitrate according to a molar ratio of 1:1 or 2:1 to obtain the magnesium complex shown in the formula I or II. The aspirin is reacted with p-nitrobenzyl alcohol to obtain an oxygen-deficiency promoting derivative of aspirin; the oxygen-deficiency promoting derivative of aspirin is reacted with the magnesium nitrate according to a molar ratio of 1:1 or 2:1 to prepare the magnesium complex shown in the formula III or IV. The application has a remarkable repairing effect on heart damage caused by myocardial ischemia and the like.

The invention relates to the technical field of molecular biology, in particular to application of a miRNA marker hsa-miR-21-5p to preparation of a kit for identifying pulmonary arterial hypertension related to heart diseases. The expression quantity of the miRNA marker hsa-miR-21-5p in plasma of coronary heart disease patients with pulmonary hypertension is obviously higher than that of healthy people and that of coronary heart disease patients without pulmonary hypertension, and the miRNA marker hsa-miR-21-5p has correlation and sensitivity to diagnosis of coronary heart disease with pulmonary hypertension, can be used as a circulating miRNA marker for auxiliary diagnosis of CPH, and can be used for clinical application. The method is used for preparing a kit for identifying CPH.

The application discloses a chemical structural formula of a biphenyl sulfonamide compound of a bis-benzimidazole, and also discloses application of the compound in preparation of a pharmaceutically acceptable salt or solvate, application of the compound and the pharmaceutically acceptable salt or solvate in preparation of a medicine for treating endothelin-dependent or angiotensin II-dependent diseases. Meanwhile, the biphenyl sulfonamide compound of the bis-benzimidazole can also be used in combination by changing substituted functional groups. The biphenyl sulfonamide compound of the bis-benzimidazole, the prepared pharmaceutically acceptable salt or solvate and the medicine prepared by the compound have pharmacological activities, and have pharmacological effects in animals including human beings, and are particularly useful in treatment or prevention of IgA nephropathy, focal segmental glomerulosclerosis, nephrotic syndrome, chronic kidney disease, diabetic nephropathy, hypertension, coronary heart disease and myocardial infarction.

The invention discloses a three-cavity micro catheter for coronary heart disease surgery, and relates to the technical field of medical equipment. Comprising a microcatheter body, and a first through cavity and a second through cavity are formed in the microcatheter body; a micro-catheter front end is arranged at the head end of the micro-catheter body; the first through cavity penetrates through the front end of the microcatheter and forms a first cavity opening, and the first through cavity penetrates through the tail end of the microcatheter body and is provided with a first cavity tube; the second through cavity penetrates through the front end of the micro catheter and forms a second cavity opening, and the second through cavity penetrates through the tail end of the micro catheter body and is provided with a second cavity tube; the front end of the micro-catheter is provided with a third cavity tube adjacent to the second through cavity, a third through cavity is arranged in the third cavity tube, the third through cavity penetrates through the third cavity tube, the head end of the third through cavity is provided with a third through cavity outlet, the head end of the third cavity tube is longer than the second cavity opening, and the third through cavity is provided with a third through cavity inlet at the joint of the third cavity tube and the front end of the micro-catheter. According to the three-cavity microcatheter, a clear contrast image can be obtained with a small amount of contrast agent, the advancing direction of the guide wire can be guided at any time, and efficiency is improved.

The invention relates to the technical field of metabolic markers, in particular to application of metabolic markers in preparation of products for detecting or diagnosing coronary heart disease adverse cardiovascular events and a construction method of a coronary heart disease adverse cardiovascular event diagnosis model. The coronary heart disease adverse cardiovascular event product is used for detecting or diagnosing coronary heart disease cardiovascular death events and / or coronary heart disease heart failure events. According to the application, the risks of death events and heart failure events of the coronary heart disease patients are predicted by using the specific differential metabolites, dense monitoring can be performed on the coronary heart disease patients, and effective customized treatment guidance is provided for clinicians.

The invention discloses an application of a compound as a CYP2E1 inhibitor, which is characterized in that the compound or a salt thereof as an inhibitor takes CYP2E1 as a target spot and is combined with the CYP2E1, and the CYP2E1 inhibitor has an inhibition effect on CYP2E1. The inhibitor can be used for preventing and treating tumors such as liver cancer, glioma, ovarian cancer, bladder cancer and gallbladder cancer. Similarly, the inhibitor can also be used for preventing and treating other inflammation-related diseases such as liver injury, fatty liver, hepatitis, hepatic fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic cerebral apoplexy, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes mellitus and the like.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for treating coronary heart disease complicated with anxiety and depression, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from coptis chinensis, rhizoma pinelliae preparata, caulis bambusae in taeniam, fried fructus aurantii, pericarpium citri reticulatae, poria cocos, vinegar-processed curcuma zedoary, astragalus membranaceus, cassia twig, angelica sinensis, ligusticum wallichii, cortex albiziae, vinegar-processed rhizoma cyperi and fried semen raphani. The traditional Chinese medicine composition has the effects of tonifying qi, activating blood and soothing liver-qi stagnation, and has a good treatment effect on coronary heart disease combined with anxiety depression through test verification.

The invention relates to a cardiovascular and cerebrovascular metabolism co-disease risk factor early warning and active health digital intelligence system, and the system comprises a digital intelligence library module, an auxiliary decision module, a digital intelligence management module, a mobile terminal, and a cloud service platform. The mobile terminal and the cloud service platform are used for obtaining the multi-modal data of a user. The auxiliary decision-making module is used for determining user portrait data and a cardiovascular risk level based on the multi-modal data acquired by the mobile terminal and the cloud service platform; the digital intelligent management module is used for generating and outputting an intervention scheme based on the user portrait data and the cardiovascular risk level determined by the aid decision making module; and the digital intelligence library module is used for storing active health knowledge and skill data, behavior and lifestyle intervention skills and generation strategies related to prevention and treatment of hyperglycemia, hyperlipidemia, hypertension, diabetes mellitus, coronary heart disease and cerebral apoplexy. The problem that in the prior art, personalized early warning and auxiliary decision-making services are lacked for cardiovascular and cerebrovascular diseases is solved.

The invention provides a composition, a traditional Chinese medicine composition and application thereof. Specifically, the invention provides a composition which comprises coix seeds, radix aconiti carmichaeli and musk. The composition can prevent and treat coronary heart disease angina pectoris, improve the attack frequency of angina pectoris, relieve the symptoms of chest distress and pain when angina pectoris attacks, and improve the long-term prognosis effect and life quality.